Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...
Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...
If congestion, postnasal drip, or sinus pressure consistently follows an Ozempic injection, there may be a link. However, if symptoms vary or occur independently of the medication schedule ...
Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
It shows visuals of existing weight loss medications known as GLP-1s, including injection pens that look like Novo Nordisk's blockbuster diabetes drug Ozempic. The ad claims those drugs are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback